Keri A Drake1, Natalie Ellington2, Jyothsna Gattineni1, Jose R Torrealba2, Allen R Hendricks3. 1. Division of Pediatric Nephrology, UT Southwestern Medical Center, 1935 Medical District Drive, Dallas, TX, 75235, USA. 2. Department of Pathology, UT Southwestern Medical Center, 6210 Harry Hines Blvd, Dallas, TX, 75390-9234, USA. 3. Department of Pathology, UT Southwestern Medical Center, 5959 Harry Hines Blvd., Suite HP3-378, Dallas, TX, 75390-9234, USA. allen.hendricks@UTSouthwestern.edu.
Abstract
BACKGROUND: C3 glomerulopathy (C3G) is defined by dominant glomerular deposition of C3 and minimal or no immunoglobulin, with two subtypes-dense deposit disease (DDD) and C3 glomerulonephritis (C3GN)-distinguished by features on electron microscopy (EM). Given that this rare disease has generally unfavorable yet highly variable outcomes, we sought out to review the histopathology, complement/genetic studies, and renal outcomes of pediatric patients with C3G at our institution. METHODS: All native kidney biopsies performed in a single pediatric hospital over a 10-year period were reviewed for features of C3G. Of 589 biopsy reports, we identified 9 patients fulfilling the diagnostic criteria for C3G and retrospectively reviewed their clinical chart and renal biopsy findings. RESULTS: We identified 4 patients with DDD, 4 with C3GN, and 1 indeterminate case, with features of both C3GN and DDD. Five patients were positive for one or more nephritic factors (C3NeF, C4NeF, C5NeF) with 1 patient additionally positive for complement factor H (CFH) autoantibody. Genetic testing done in 5 of the 9 patients failed to identify any causative mutations. Three patients showed progressive renal dysfunction over a mean follow-up period of 33 months. CONCLUSIONS: Complement and genetic studies are now routinely recommended for patients with a histopathological diagnosis of C3G. Careful interpretation of these studies and their prognostic and therapeutic implications in conjunction with biopsy findings is needed to further understand the pathophysiology of this rare disease in children.
BACKGROUND:C3 glomerulopathy (C3G) is defined by dominant glomerular deposition of C3 and minimal or no immunoglobulin, with two subtypes-dense deposit disease (DDD) and C3 glomerulonephritis (C3GN)-distinguished by features on electron microscopy (EM). Given that this rare disease has generally unfavorable yet highly variable outcomes, we sought out to review the histopathology, complement/genetic studies, and renal outcomes of pediatric patients with C3G at our institution. METHODS: All native kidney biopsies performed in a single pediatric hospital over a 10-year period were reviewed for features of C3G. Of 589 biopsy reports, we identified 9 patients fulfilling the diagnostic criteria for C3G and retrospectively reviewed their clinical chart and renal biopsy findings. RESULTS: We identified 4 patients with DDD, 4 with C3GN, and 1 indeterminate case, with features of both C3GN and DDD. Five patients were positive for one or more nephritic factors (C3NeF, C4NeF, C5NeF) with 1 patient additionally positive for complement factor H (CFH) autoantibody. Genetic testing done in 5 of the 9 patients failed to identify any causative mutations. Three patients showed progressive renal dysfunction over a mean follow-up period of 33 months. CONCLUSIONS: Complement and genetic studies are now routinely recommended for patients with a histopathological diagnosis of C3G. Careful interpretation of these studies and their prognostic and therapeutic implications in conjunction with biopsy findings is needed to further understand the pathophysiology of this rare disease in children.
Authors: Andrew S Bomback; Dominick Santoriello; Rupali S Avasare; Renu Regunathan-Shenk; Pietro A Canetta; Wooin Ahn; Jai Radhakrishnan; Maddalena Marasa; Paul E Rosenstiel; Leal C Herlitz; Glen S Markowitz; Vivette D D'Agati; Gerald B Appel Journal: Kidney Int Date: 2018-01-06 Impact factor: 10.612
Authors: Xue Xiao; Cybele Ghossein; Agustín Tortajada; Yuzhou Zhang; Nicole Meyer; Michael Jones; Nicolo Ghiringhelli Borsa; Carla M Nester; Christie P Thomas; Santiago Rodríquez de Córdoba; Richard J H Smith Journal: Mol Immunol Date: 2016-08-01 Impact factor: 4.407
Authors: Sanjeev Sethi; Fernando C Fervenza; Yuzhou Zhang; Ladan Zand; Nicole C Meyer; Nicolò Borsa; Samih H Nasr; Richard J H Smith Journal: Kidney Int Date: 2012-12-12 Impact factor: 10.612
Authors: Sanjeev Sethi; Fernando C Fervenza; Yuzhou Zhang; Ladan Zand; Julie A Vrana; Samih H Nasr; Jason D Theis; Ahmet Dogan; Richard J H Smith Journal: Kidney Int Date: 2012-08 Impact factor: 10.612
Authors: Edwin K S Wong; Kevin J Marchbank; Hannah Lomax-Browne; Isabel Y Pappworth; Harriet Denton; Katie Cooke; Sophie Ward; Amy-Claire McLoughlin; Grant Richardson; Valerie Wilson; Claire L Harris; B Paul Morgan; Svetlana Hakobyan; Paul McAlinden; Daniel P Gale; Heather Maxwell; Martin Christian; Roger Malcomson; Timothy H J Goodship; Stephen D Marks; Matthew C Pickering; David Kavanagh; H Terence Cook; Sally A Johnson Journal: Clin J Am Soc Nephrol Date: 2021-09-22 Impact factor: 8.237
Authors: Marloes A H M Michels; Kioa L Wijnsma; Roel A J Kurvers; Dineke Westra; Michiel F Schreuder; Joanna A E van Wijk; Antonia H M Bouts; Valentina Gracchi; Flore A P T Engels; Mandy G Keijzer-Veen; Eiske M Dorresteijn; Elena B Volokhina; Lambertus P W J van den Heuvel; Nicole C A J van de Kar Journal: Pediatr Nephrol Date: 2021-09-02 Impact factor: 3.714